Mediate hepatic IRF8 rescue, inhibiting TAMs infiltration and decreasing expression of CCL20, and significantly inhibit HCC progression, enhancing the response to anti‐PD‐1 therapy. This evidence concerns the gene IRF8 and hepatocellular carcinoma.